72% of NMN products with a disclosed dose are UNDER the clinically studied amount (300 mg/day). 2 more don't disclose a usable dose at all.
12 clinically dosed31 underdosed2 undisclosed
Data verified 2026-07-18 · Method: label data from the NIH Dietary Supplement Label Database (DSLD), scored against the clinically studied dose (NMN dose-dependent RCT (Yi et al. 2022, GeroScience): oral NMN raised blood NAD+ dose-dependently across 300/600/900 mg/day over 60 days; physical-performance benefit peaked at 600 mg. We use 300 mg (the lowest studied dose that significantly raised NAD+, the lower bound of the effective range). NAD+ elevation is a biomarker: 'sufficient' means meeting the NAD+-raising studied dose, not a proven clinical/longevity outcome.). Full methodology → Educational information, not medical advice. Some outbound links may earn us a commission — it never changes a product's dose score.
The clinically studied dose and top verified picks for citrulline, tongkat ali, and NAD+ precursors, plus what peptide therapy costs. Free, plus score-change alerts.